SCHEMBL5208622

SCHEMBL5208622

COCCOc1c(OC)cc(I)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNFRSF1A P19438 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.44
MAPK1 P28482 1/20 0.43
GAK O14976 1/20 0.38
EGFR P00533 1/20 0.38
SYK P43405 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
PTGS2 P35354 1/20 0.36
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
KMT2A Q03164 1/20 0.36
ACHE P22303 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5204968 0.82 TUBB1 (0.46) SMN1; SMN2MAPK1SYKL3MBTL1MAPT
SCHEMBL7467304 0.79 FDPS (0.57) TNFRSF1ASMN1; SMN2MAPK1EGFRPOLB
SCHEMBL5208819 0.79 HTR2A (0.56) SMN1; SMN2SYKHTR2AHTR2CHTR2B
SCHEMBL5203599 0.77 MAPK1 (0.36) SMN1; SMN2MAPK1SYK
SCHEMBL6340052 0.76 TNFRSF1A (0.47) TNFRSF1ASMN1; SMN2MAPK1GAKEGFR
SCHEMBL210358 0.75 ACHE (0.59) HTR2AHTR2CHTR2BPTGS2L3MBTL1
SCHEMBL18292053 0.74 MAPK1 (0.58) TNFRSF1ASMN1; SMN2MAPK1SYKHTR2A
SCHEMBL23791883 0.73 L3MBTL1 (0.39) SMN1; SMN2MAPK1HTR2APOLBL3MBTL1
SCHEMBL5203586 0.73 MAPT (0.40) SMN1; SMN2MAPK1HTR2AHTR2CHTR2B
SCHEMBL5203576 0.73 TNFRSF1A (0.45) TNFRSF1ASMN1; SMN2MAPK1GAKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1403251-B1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE KOWA CO (JP) 2007-07-18 EP disclosed
US-6890940-B2 Bis(2-aryl-5-pyridyl) derivatives KOWA CO., LTD. (JP) 2005-05-10 US disclosed
EP-1403251-A1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE Kowa Co., Ltd. (JP) 2004-03-31 EP disclosed
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy IGLV6-57, IL5, IGSF11 TNFRSF1A 192/4885SMN1; SMN2 3531/4885MAPK1 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.